-
Je něco špatně v tomto záznamu ?
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
MS. Infante, J. Salmanton-García, A. Fernández-Cruz, F. Marchesi, O. Jaksic, B. Weinbergerová, C. Besson, RF. Duarte, F. Itri, T. Valković, T. Szotkovski, A. Busca, A. Guidetti, A. Glenthøj, GP. Collins, V. Bonuomo, U. Sili, GC. Seval, M....
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
PubMed
36276116
DOI
10.3389/fonc.2022.992137
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
Amsterdam UMC location VUmc Amsterdam Netherlands
Ankara University Ankara Turkey
ASST Grande Ospedale Metropolitano Niguarda Milan Italy
Azienda Ospedaliera San Gerardo Monza Monza Italy
Centre Hospitalier de Versailles Versailles France
Communicable Disease Center Hamad Medical Corporation Doha Qatar
COVID Hospital Batajnica Belgrade Serbia
Croatian Cooperative Group for Hematological Diseases Zagreb Croatia
Departament de Medicina Universitat Autònoma de Barcelona Bellaterra Spain
Department of Hematology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark
Department of Hematology University Hospital Dubrava Zagreb Croatia
Department of Medicine Section of Hematology University of Verona Verona Italy
Department of Nephrology and Infectious Diseases AZ Sint Jan Brugge Oostende AV Brugge Belgium
Division of Hematology and Oncology Weill Cornell Medicine New York NY United States
Faculty of Medicine and Faculty of Health Studies University of Rijeka Rijeka Croatia
Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
German Centre for Infection Research Partner Site Bonn Cologne Cologne Germany
Health Research Institute IIS FJD Fundacion Jimenez Diaz University Hospital Madrid Spain
Health Research Institute IIS FJD Fundación Jimenez Diaz University Hospital Madrid Spain
Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute Rome Italy
Hematology Deparment Hospital Universitario Infanta Leonor Madrid Spain>
Hematology Department Hospital Universitario 12 de Octubre Madrid Spain
Hematology Department Hospital Universitario de Salamanca Salamanca Spain
Hematology Unit ASST Spedali Civili Brescia Italy
Hematology Unit Center for Translational Medicine Azienda USL Toscana NordOvest Livorno Italy
Hematology Unit Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Hematology Unit Università Cattolica del Sacro Cuore Rome Italy
Hospital Campus Barcelona Spain
Hospital Nuestra Señora de Sonsoles Ávila Spain
Hospital Universitario Puerta de Hierro Majadahonda Spain
IBSAL Centro de Investigación del Cáncer IBMCC Salamanca Spain
Institute of Hematology and Blood Transfusion Prague Czechia
King's College Hospital London United Kingdom
King's College London London United Kingdom
La Paz University Hospital Madrid Spain
Laikon General Hospital Athens Greece
Medizinische Klinik 2 Klinikum rechts der Isar TU München Munich Germany
NIHR Oxford Biomedical Research Centre Churchill Hospital Oxford United Kingdom
Portuguese Institute of Oncology Lisbon Portugal
San Luigi Gonzaga Hospital Orbassano Orbassano Italy
Stem Cell Transplant Center AOU Citta' della Salute e della Scienza Turin Italy
U O Ematologia e Centro Trapianti Midollo Osseo Ospedale Maggiore Parma Italy
Università Milano Bicocca Milan Italy
University Clinic of Hematology Skopje North Macedonia
University Hospital Centre Rijeka Rijeka Croatia
University Hospital Olomouc Olomouc Czechia
University Hospital Ostrava Ostrava Czechia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22031622
- 003
- CZ-PrNML
- 005
- 20230127131236.0
- 007
- ta
- 008
- 230119s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fonc.2022.992137 $2 doi
- 035 __
- $a (PubMed)36276116
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Infante, Maria Stefania $u Hematology Deparment, Hospital Universitario Infanta Leonor, Madrid, Spain>
- 245 10
- $a B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA) / $c MS. Infante, J. Salmanton-García, A. Fernández-Cruz, F. Marchesi, O. Jaksic, B. Weinbergerová, C. Besson, RF. Duarte, F. Itri, T. Valković, T. Szotkovski, A. Busca, A. Guidetti, A. Glenthøj, GP. Collins, V. Bonuomo, U. Sili, GC. Seval, M. Machado, R. Cordoba, O. Blennow, G. Abu-Zeinah, S. Lamure, A. Kulasekararaj, I. Falces-Romero, C. Cattaneo, J. Van Doesum, K. Piukovics, AS. Omrani, G. Magliano, MP. Ledoux, C. de Ramon, A. Cabirta, L. Verga, A. López-García, MG. Da Silva, Z. Stojanoski, S. Meers, T. Lahmer, S. Martín-Pérez, J. Dávila-Vals, J. Van Praet, M. Samarkos, YM. Bilgin, LK. Karlsson, J. Batinić, A. Nordlander, M. Schönlein, M. Hoenigl, Z. Ráčil, M. Mladenović, M. Hanakova, GPM. Zambrotta, N. De Jonge, T. Adžić-Vukičević, R. Nunes-Rodrigues, L. Prezioso, M. Navrátil, M. Marchetti, A. Cuccaro, M. Calbacho, A. Giordano, OA. Cornely, JÁ. Hernández-Rivas, L. Pagano
- 520 9_
- $a Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Media $a Patients with lymphoproliferative diseases LPD are vulnerable to severe acute respiratory syndrome coronavirus 2 SARS CoV 2 infection Here we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia CLL or non Hodgkin Lymphoma NHL treated with targeted drugs and laboratory confirmed COVID 19 diagnosed between February 2020 and January 2022 Median follow up $a Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Salmanton-García, Jon $u Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany $u Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), University of Cologne, Cologne, Germany
- 700 1_
- $a Fernández-Cruz, Ana $u Hospital Universitario Puerta de Hierro, Majadahonda, Spain
- 700 1_
- $a Marchesi, Francesco $u Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy
- 700 1_
- $a Jaksic, Ozren $u Department of Hematology, University Hospital Dubrava, Zagreb, Croatia
- 700 1_
- $a Weinbergerová, Barbora $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czechia
- 700 1_
- $a Besson, Caroline $u Centre Hospitalier de Versailles, Versailles, France
- 700 1_
- $a Duarte, Rafael F $u Hospital Universitario Puerta de Hierro, Majadahonda, Spain
- 700 1_
- $a Itri, Federico $u San Luigi Gonzaga Hospital - Orbassano, Orbassano, Italy
- 700 1_
- $a Valković, Toni $u University Hospital Centre Rijeka, Rijeka, Croatia $u Croatian Cooperative Group for Hematological Diseases (CROHEM), Zagreb, Croatia $u Faculty of Medicine and Faculty of Health Studies University of Rijeka, Rijeka, Croatia
- 700 1_
- $a Szotkovski, Tomáš $u University Hospital Olomouc, Olomouc, Czechia
- 700 1_
- $a Busca, Alessandro $u Stem Cell Transplant Center, AOU Citta' della Salute e della Scienza, Turin, Italy
- 700 1_
- $a Guidetti, Anna $u Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- 700 1_
- $a Glenthøj, Andreas $u Department of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
- 700 1_
- $a Collins, Graham P $u NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom
- 700 1_
- $a Bonuomo, Valentina $u Department of Medicine, Section of Hematology, University of Verona, Verona, Italy
- 700 1_
- $a Sili, Uluhan $u Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Marmara University, Istanbul, Turkey
- 700 1_
- $a Seval, Guldane Cengiz $u Ankara University, Ankara, Turkey
- 700 1_
- $a Machado, Marina $u Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 700 1_
- $a Cordoba, Raul $u Health Research Institute IIS-FJD, Fundación Jimenez Diaz University Hospital, Madrid, Spain
- 700 1_
- $a Blennow, Ola $u Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Marmara University, Istanbul, Turkey
- 700 1_
- $a Abu-Zeinah, Ghaith $u Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY, United States
- 700 1_
- $a Lamure, Sylvain $u Departement d'Hematologie Clinique, CHU de Montpellier, UMR-CNRS 5535, Universite de Montpellier, Montpellier, France
- 700 1_
- $a Kulasekararaj, Austin $u King's College Hospital, London, United Kingdom $u King's College London, London, United Kingdom
- 700 1_
- $a Falces-Romero, Iker $u La Paz University Hospital, Madrid, Spain
- 700 1_
- $a Cattaneo, Chiara $u Hematology Unit, ASST-Spedali Civili, Brescia, Italy
- 700 1_
- $a Van Doesum, Jaap $u University Medical Center Groningen, Groningen, Netherlands
- 700 1_
- $a Piukovics, Klára $u Department of Internal Medicine, Albert Szent-Györgyi Health Center, Faculty of Medicine University of Szeged, Szeged, Hungary
- 700 1_
- $a Omrani, Ali S $u Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar
- 700 1_
- $a Magliano, Gabriele $u ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- 700 1_
- $a Ledoux, Marie-Pierre $u ICANS, Strasbourg, France
- 700 1_
- $a de Ramon, Cristina $u Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain $u IBSAL, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain
- 700 1_
- $a Cabirta, Alba $u Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona, Spain $u Hospital Campus, Barcelona, Spain $u Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain
- 700 1_
- $a Verga, Luisa $u Azienda Ospedaliera San Gerardo - Monza, Monza, Italy $u Università Milano-Bicocca, Milan, Italy
- 700 1_
- $a López-García, Alberto $u Health Research Institute IIS-FJD, Fundacion Jimenez Diaz University Hospital, Madrid, Spain
- 700 1_
- $a Da Silva, Maria Gomes $u Portuguese Institute of Oncology, Lisbon, Portugal
- 700 1_
- $a Stojanoski, Zlate $u University Clinic of Hematology, Skopje, North Macedonia
- 700 1_
- $a Meers, Stef $u AZ KLINA, Brasschaat, Belgium
- 700 1_
- $a Lahmer, Tobias $u Medizinische Klinik II, Klinikum rechts der Isar, TU München, Munich, Germany
- 700 1_
- $a Martín-Pérez, Sonia $u Hospital Nuestra Señora de Sonsoles, Ávila, Spain
- 700 1_
- $a Dávila-Vals, Julio $u Hospital Nuestra Señora de Sonsoles, Ávila, Spain
- 700 1_
- $a Van Praet, Jens $u Department of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium
- 700 1_
- $a Samarkos, Michail $u Laikon General Hospital, Athens, Greece
- 700 1_
- $a Bilgin, Yavuz M $u ADRZ, Goes, Netherlands
- 700 1_
- $a Karlsson, Linda Katharina $u Department of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
- 700 1_
- $a Batinić, Josip $u UHC Zagreb, Zagreb, Croatia
- 700 1_
- $a Nordlander, Anna $u Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Marmara University, Istanbul, Turkey
- 700 1_
- $a Schönlein, Martin $u Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Hoenigl, Martin $u Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, United States $u Clinical and Translational Fungal-Working Group, University of California San Diego, La Jolla, CA, United States $u Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria
- 700 1_
- $a Ráčil, Zdeněk $u Institute of Hematology and Blood Transfusion, Prague, Czechia
- 700 1_
- $a Mladenović, Miloš $u COVID Hospital "Batajnica", Belgrade, Serbia
- 700 1_
- $a Hanakova, Michaela $u Institute of Hematology and Blood Transfusion, Prague, Czechia
- 700 1_
- $a Zambrotta, Giovanni Paolo Maria $u Azienda Ospedaliera San Gerardo - Monza, Monza, Italy $u Università Milano-Bicocca, Milan, Italy
- 700 1_
- $a De Jonge, Nick $u Amsterdam UMC, location VUmc, Amsterdam, Netherlands
- 700 1_
- $a Adžić-Vukičević, Tatjana $u COVID Hospital "Batajnica", Belgrade, Serbia
- 700 1_
- $a Nunes-Rodrigues, Raquel $u Portuguese Institute of Oncology, Lisbon, Portugal
- 700 1_
- $a Prezioso, Lucia $u U.O. Ematologia e Centro Trapianti Midollo Osseo, Ospedale Maggiore, Parma, Italy
- 700 1_
- $a Navrátil, Milan $u University Hospital Ostrava, Ostrava, Czechia
- 700 1_
- $a Marchetti, Monia $u Hematology and BMT Unit, Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
- 700 1_
- $a Cuccaro, Annarosa $u Hematology Unit, Center for Translational Medicine, Azienda USL Toscana NordOvest, Livorno, Italy
- 700 1_
- $a Calbacho, Maria $u Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- 700 1_
- $a Giordano, Antonio $u Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy $u Hematology Unit, Università Cattolica del Sacro Cuore, Rome, Italy
- 700 1_
- $a Cornely, Oliver A $u Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany $u Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), University of Cologne, Cologne, Germany $u University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany $u University of Cologne, Faculty of Medicine and University Hospital Cologne, Center for Molecular Medicine Cologne (CMMC), Cologne, Germany $u German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany
- 700 1_
- $a Hernández-Rivas, José-Ángel $u Hematology Deparment, Hospital Universitario Infanta Leonor, Madrid, Spain>
- 700 1_
- $a Pagano, Livio $u Hematology Unit, Università Cattolica del Sacro Cuore, Rome, Italy
- 773 0_
- $w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 12, č. - (2022), s. 992137
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36276116 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230119 $b ABA008
- 991 __
- $a 20230127131228 $b ABA008
- 999 __
- $a ok $b bmc $g 1889574 $s 1182955
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2022 $b 12 $c - $d 992137 $e 20221003 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
- LZP __
- $a Pubmed-20230119
